Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myeloid Inhibitory C-type Lectin-like Receptor (CLEC12A)
- Target
- CLEC12A
- Molecular classification
- C-type lectin-like domain (CTLD) superfamily, Type I transmembrane protein, Receptor
01
Overview
CLEC12A is a type I transmembrane protein and an inhibitory receptor expressed on myeloid cells. It belongs to the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily and plays a key role in regulating immune responses and maintaining immune homeostasis. It negatively regulates myeloid cell activation and inflammation by interacting with ligands like MSU crystals and recruiting phosphatases to its ITIM domain.
- Other names
- CLL-1CLL1DCAL-2MICLCD371C-type lectin domain family 12 member A
02
Mechanism of action
Inhibition of myeloid cell activation via ITIM signaling, recruitment of phosphatases (SHP-1, SHP-2), and negative regulation of PI3K/Akt/p38 MAPK pathway.
03
Biological functions
Negative regulation of myeloid cell activationImmune homeostasisInflammation controlLigand recognition
04
Disease associations
Acute Myeloid Leukemia (AML)Inflammation
05
Safety considerations
Potential for off-target effects in CAR-T therapiesComplexity of immune regulation may lead to unintended consequences
06
Biomarkers
CLEC12A expression level in AML cellsCorrelation with immune infiltration patterns in AML tumors
Beyond the preview
Go deeper on Myeloid Inhibitory C-type Lectin-like Receptor (CLEC12A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myeloid Inhibitory C-type Lectin-like Receptor (CLEC12A).